Genetron is a diagnostics & research business based in the US. Genetron shares (GTH) are listed on the NASDAQ and all prices are listed in US Dollars. Genetron employs 993 staff and has a trailing 12-month revenue of around $650.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $2.08 - $4.05 |
| 50-day moving average | $3.87 |
| 200-day moving average | $3.33 |
| Wall St. target price | $1.34 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.62 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2024-04-10
| 1 week (2024-08-24) | nan% |
|---|---|
| 1 month (2024-07-31) | nan% |
| 3 months (2024-05-31) | nan% |
| 6 months (2024-03-04) | -100.00% |
| 1 year (2023-09-01) | -100.00% |
|---|---|
| 2 years (2022-09-02) | -100.00% |
| 3 years (2021-09-03) | 14.21 |
| 5 years (2019-08-31) | N/A |
| Revenue TTM | $650.7 million |
|---|---|
| Gross profit TTM | $338 million |
| Return on assets TTM | -35.2% |
| Return on equity TTM | -92.2% |
| Profit margin | -124.24% |
| Book value | $17.90 |
| Market Capitalization | $127.3 million |
TTM: trailing 12 months
We're not expecting Genetron to pay a dividend over the next 12 months.
Genetron's shares were split on a 1:3 basis on 25 October 2023. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genetron shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Genetron shares which in turn could have impacted Genetron's share price.
Over the last 12 months, Genetron's shares have ranged in value from as little as $2.079 up to $4.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genetron's is 0.498. This would suggest that Genetron's shares are less volatile than average (for this exchange).
Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China. .
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
A deep dive into the highlights and limitations of Frec.
Compare pros, cons, research tools and reviews for these two trading platforms.
What you need to know about investing in the leading indicator for the overall US stock market.
An online REIT with low fees, consistent dividends and a stable portfolio, but a brief track record.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.